Worldwide Healthcare Trust PLC Edison issues review on Worldwide Healthcare Trust
07 January 2020 - 11:27PM
RNS Non-Regulatory
TIDMWWH
Worldwide Healthcare Trust PLC
07 January 2020
London, UK, 7 January 2020
Edison issues review on Worldwide Healthcare Trust (WWH)
Worldwide Healthcare Trust (WWH) is managed by Sven Borho and
Trevor Polischuk at OrbiMed. They remain very constructive on the
prospects for the global healthcare sector - despite headline risk
ahead of the 2020 US presidential election - citing industry
innovation, which they suggest is at 'unparalleled' levels, and has
historically been an important driver of the sector's performance.
Although investor concerns about drug pricing in the US remain,
Borho and Polischuk say that pharma and biotech companies are
'still getting paid and are generating attractive returns'. In
addition to opportunities in developed markets, they are also
finding interesting investment ideas in China, due to higher
product approval standards and a relaxation of listing requirements
for fledgling companies.
WWH's shares regularly trade close to NAV (the board targets a
maximum discount of 6%). The trust's current 0.4% premium to
cum-income NAV compares with an average premium of 0.1% over the
last three years, and average discounts of 0.1%, 2.0% and 4.3% over
the last one, five and 10 years respectively. While WWH is managed
for capital growth, it also pays regular six-monthly dividends, and
currently yields 0.9%.
Click here to view the full report.
All reports published by Edison are available to download free
of charge from its website
www.edisongroup.com
About Edison: Edison is an investment research and advisory
company, with offices in North America, Europe, the Middle East and
AsiaPac. The heart of Edison is our world-renowned equity research
platform and deep multi-sector expertise. At Edison Investment
Research, our research is widely read by international investors,
advisers and stakeholders. Edison Advisors leverages our core
research platform to provide differentiated services including
investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct
Authority.
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
For more information please contact Edison:
Mel Jenner, +44 (0)20 3077 5720
Sarah Godfrey, +44 (0)20 3681 2519
investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison
on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABRMTTMTTMBIM
(END) Dow Jones Newswires
January 07, 2020 07:27 ET (12:27 GMT)
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Sep 2023 to Sep 2024